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Abstract Recently, it was shown that aminopeptidase N (E.C. 
3.4.11.2, CD13) is up-regulated during mitogenic stimulation of 
peripheral T-cells. In this study, we demonstrate that the half-life 
of APN mRNA was considerably prolonged in these cells leading 
to a 2.7-fold increase of APN transcript level. The apparent half-
life time of the APN transcript was investigated by the RNA 
synthesis inhibitor-chase method using actinomycin D. The 
steady-state APN mRNA levels was determined by a competitive 
RT-PCR. The half-lives estimated in resting T-cells, natural 
killer cells and permanently growing tumour cells varied between 
3.5 and 6 h. Finally, nuclear run-on assays revealed that the APN 
gene expression of stimulated T-cells is controlled by increased 
promoter activity as well. These studies suggest a control of APN 
gene expression at the post-transcriptional level in addition to 
promoter-mediated regulation. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
The cell-surface antigen C D 13, also known as aminopepti-
dase N (APN, E.C. 3.4.11.2), is a 150 k D a glycoprotein [1,2]. 
It is a stalked integral membrane peptidase, mainly expressed 
in the small intestinal and kidney brush borders but also 
found in brain, lung, liver and in the hematopoietic system 
[3-5]. Studies aimed at the functional role of A P N revealed 
that this enzyme is involved in different processes such as 
hydrolysis of nutrients, inactivation of bioactive peptides, 
binding of corona viruses, mediating CMV infection, regula-
tion of tumour-cell invasion, and degradation of the extra-
cellular matrix and antigen presentation [3,6-12]. 
Until recently, in the hematopoietic system, C D 13 expres-
sion was exclusively detected on myelomonocytic cells [2,5]. 
However, it is now well established that increased C D 13 sur-
face expression is frequently detected on malignant B-cells, 
tumour-infiltrating lymphocytes (TIL), T-lymphocytes derived 
from inflamed tissues as well as mitogen activated T-cells [13-
16]. The induction of C D 13 expression on mitogen-activated 
T-cells as well as increased C D 13 surface expression on T-cells 
derived from inflamed tissues is always accompanied by in-
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phosphate-buffered saline; PHA, phytohemagglutinine; PMA, phor-
bol 12-acetate 13-myristate; RT-PCR, reverse transcription-polymer-
ase chain reaction; SDS, sodium dodecyl sulfate; SSC, standard 
sodium citrate 
creased levels of corresponding enzymatic activity and APN 
m R N A [13,16,19]. 
The aim of this study was to investigate APN gene regula-
tion in mitogen-stimulated T-cells. Here, we present data sug-
gesting that APN gene expression of these cells is controlled at 
both the transcriptional and post-transcriptional level. 
2. Materials and methods 
2.1. Cell lines, culture, preparation and mitogenic stimulation of cells 
U937 and H9 cells were obtained from ATCC (USA) or DSM 
(Braunschweig, Germany), respectively. Cells were grown in IMDM 
(Gibco) supplemented with 10% foetal calf serum (Gibco BRL) and 
60 U/ml penicillin (Gibco BRL). 
Peripheral T-cells were enriched from the MNC population by ny-
lon adherence as described by others [17]. FACS analyses indicated a 
purity of CD3+ cells between 85 and 95%. Natural killer (NK) cells 
were enriched by depletion of CD3+ and CD19+ cells using the 
MACS system (Miltenyi Biotec) as previously described [18]. In gen-
eral, NK cells consist of more than 90% CD16+/CD56+ cells, whereas 
CD3+ cells were less than 5%. 
Purified T-cells were stimulated by 5 |ig/ml PHA (Boehringer 
Mannheim) in the presence of 10 ng/ml PMA (Sigma) for 3 days 
[16]. NK cells were stimulated by 1000 U/ml IL-2 for 3 days [18]. 
2.2. Enzymatic assay 
Ala-pNA hydrolysing activity of cells or their lysates, respectively, 
was determined in triplicate by measuring the hydrolysis of the chro-
mogenic substrate Ala-pNA (2.5 mM) as described previously [16]. 
2.3. Competitive PCR 
RNA samples of resting or stimulated cells were obtained using the 
'RNeasy' kit (Qiagen) according to the manufacturer's instructions. 
Total RNA (250 ng-1 ug) was mixed with an aliquot of a standard 
APN mRNA fragment and transcribed into cDNA by 50 U of 
MMLV reverse transcriptase (USB) using an APN-specific primer 
(5'-gcggtagaagcccgccaggtca). 
An aliquot of the cDNA mixture was used directly for enzymatic 
amplifications which were performed in a 40 (xl reaction volume con-
taining 0.5 U 'Gold-Star' polymerase (Eurogentec), 0.25 mM dNTP, 
2.5 mM MgCl2, 0.2 pmol of primers (forward: 5'-gccgtgtgcacaat-
catcgcact; reverse: 5'-caccagggagcccttgaggtg) and IX reaction buffer 
(Eurogentec) in the thermocycler Autogene II (CLF, Emmersacker, 
Germany). Initial denaturation at 94°C for 3 min was followed by 30 
cycles with denaturation at 96.5°C for 0.4 min, annealing at 54°C for 
0.6 min and elongation at 72°C for 0.8 min. The final extension step 
was 72°C for 10 min. An aliquot of the PCR reaction was electro-
phoretically separated in a 1.6% agarose gel (Biozym, Germany), 
documented by a video image system (GelPrint 2000i, MWG Biotech, 
Germany) and densitometrically analysed using RFLP 3.0 software 
(Scanalytics, USA). 
2.4. Nuclear run-on assay 
Nuclear run-on assays were performed from isolated nuclei derived 
from resting and stimulated T-cells as described by others with some 
modifications [20], Briefly, 1-2 XlO7 cells were harvested, incubated 
on ice for 10 min, washed twice in ice-cold PBS (pH 7.4) and lysed in 
NP-40 buffer (10 mM Tris-HCl, pH 7.4; 10 mM NaCl; 3 mM MgCl2; 
0.5% NP-40). After an incubation on ice for 5 min, nuclei were iso-
lated by centrifugation (500 Xg, 4°C, 5 min), resuspended in NP-40 
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Fig. 1. Determination of the APN mRNA content of restin (A) or stimulated (B) T-cells after RNA synthesis inhibition by actinomycin D. 
Cells were cultured in the presence of 5 ug/ml actinomycin D for 6 h, then their APN-transcript levels were estimated as described in Section 
2. The figure represents three independent experiments using the same T-cells. Equal amounts of RNA and standard fragment were used in the 
both samples of each experiment (0 h, 6 h). Summarizing data from six T-cell populations, resting or stimulated T-cells contained 2.9 ± 1.6 or 
7.8 ± 3.9 pg APN mRNA/ug RNA, respectively. 
buffer again and centrifugation was repeated. The nuclear pellets were 
resuspended in 100 ju.1 of storage buffer containing 50 mM Tris-HCl 
(pH 8.3), 40% glycerol, 5 mM MgCl2, 0.1 mM EDTA and stored at 
—70°C until use. 
The frozen nuclei (100 ul) were mixed with 100 ul of 2X reaction 
buffer (10 mM Tris-HCl, pH 8.0; 5 mM MgCl2; 0.3 M KC1; 5 mM 
DTT; 1 mM ATP; 1 mM CTP; 1 mM GTP; 50 uM UTP) (Boeh-
ringer Mannheim) and 10 uCi [a33P]UTP (800 Ci/mmol, ICN Bio-
medicals, Germany). The reaction mixture was incubated at 30°C for 
30 min. The labelled nuclear extract was subsequently treated with 
DNase I, proteinase K and then twice extracted with phenol/chloro-
form, precipitated by ethanol, dried and resolved in 200 ul of aqua 
bidest. 
An aliquot of this solution was used to determine the specific ac-
tivity of the nuclear lysate using the counter SMG 20046 (RFT, Ger-
many). DNA slot-blots were prepared using the plasmid pSKAPN 
containing the full-length APN cDNA (kind gift from A.T. Look [4]). 
Hybridization experiments were performed in 5XSSC containing 
2% blocking reagent (Boehringer, Mannheim), 0.1% JV-laurylsarco-
sine, 0.02% SDS, 50% formamide at 42°C for 20 h. Membranes 
were washed twice in 2XSSC at room temperature for 15 min and 
once in 1 X SSC at 42°C for 30 min. Hybridization signals were de-
tected using a phosphoimager (Bas 1000, Fuji) and quantified using 
software RFLP 3.0 (Scanalytics, USA). 
3. Results 
3.1. Half-life time of APN transcripts in hematopoietic cells 
The rate of decay of A P N m R N A in different hemato-
poietic cells was investigated using the R N A synthesis inhib-
itor actinomycin D . Cells were cultured in the presence of 
5 |J.g/ml actinomycin D for 1-6 h. At different times, their 
A P N m R N A content was quantified using a competitive 
RT -PCR approach. The inhibition of newly transcribed mes-
senger R N A by actinomycin D leads to a continued decrease 
of m R N A species, the time course of which is depended on 
their rates of decay. The reduction of A P N R N A level is 
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Fig. 2. Estimation of APN mRNA half-life time in resting and mitogen-stimulated T-cells. The graphs represent data obtained by competitive 
RT-PCR as shown in Fig. 1 using T-cells derived from six healthy donors. 
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Table 1 
Half-life times of APN transcripts in different hematopoietic cells 
Cells Half-life of APN mRNA(h) APN mRNA stabilization after stimulation 
Resting T-cells 
Resting NK cells 
T-cell line H9 
Histiocytic cell line U937 
3.5 ±0.7 (n = 6) 
6 ±1.9 (» = 3) 
3.5 ±1.9 (« = 3) 
4.5 ± 0.9 (n = 3) 
yes 
yes 
yes 
not determined 
Half-life times were determined by competitive RT-PCR as demonstrated in Fig. 1. 
Data represent means of at least three experiments («). 
No noticeable decrease of steady-state APN mRNA level was observed in stimulated T-, NK and H9 cells until 6 h co-culture with actinomycin D 
as shown for stimulated T-cells in Fig. 2. 
measured as the time-dependent decrease of the ratio between 
the APN wild-type and the APN standard fragment in RT-
PCR. Fig. 1A represents three independent quantification ex-
periments using resting T-cells from one donor. Summarizing 
the data obtained with resting T-cells from six healthy donors, 
the half-life time of APN transcript in resting T-cells was 
determined to be approximately 3.5 h (Fig. 2). The apparent 
half-life of APN transcript in resting NK cells was estimated 
as about 6 hours, however, NK-cell data showed more var-
iance than those of T-cells (Table 1). The APN mRNA half-
lives of permanently growing tumour cells such as the T-cell 
line H9 or the histiocytic cell line U937 were estimated to be 
3.5 or 4.5 h, respectively (Table 1). 
3.2. Stabilization of APN transcript and increase of APN gene 
promoter activity in stimulated T-cells 
Purified resting T-cells were stimulated for 3 days as de-
scribed in Section 2. The induction of APN expression was 
confirmed by measuring APN-derived enzymatic activity. For 
instance, stimulated T-cells contained 15-30 pkat/106 cells 
Ala-pNA hydrolysing activity compared to 4-7 pkat/106 cells 
determined in resting T-cells. The steady-state level of APN 
mRNA was increased 2.7 ± 1.4-fold in these cells. Interest-
ingly, the half-lives of the APN transcript was considerably 
prolonged in stimulated cells compared to their unstimulated 
counterparts. The APN mRNA level of stimulated T-cells 
remained unchanged up to 6 h of cultivation in the presence 
of actinomycin D as shown in Figs. IB and 2. Furthermore, a 
stabilization of APN transcript was also observed in stimu-
lated NK and H9 cells (data not shown). 
To investigate whether the promoter activity of the APN 
gene additionally contributes to the increased steady-state 
APN transcript levels in stimulated T-cells, nuclear run-on 
assays using nuclei derived from these cells were performed. 
Slot-blots were hybridized with equal amounts of labelled 
nuclear lysates. Densitometrical analysis of hybridization sig-
nals revealed an increase of promoter activity up to 
172.5 ±38.9% (« = 3) in stimulated T-cells compared to those 
of resting T-cells (data not shown). 
4. Discussion 
During the last years it has been shown that within the 
hematopoietic system CD 13 expression is not restricted to 
myelomonocytic cells. It has been longly known that this anti-
gen is frequently expressed on lymphoid tumour clones. The 
frequencies of such CD13-positive clones vary between 5 and 
30% [13,21]. Recently, it has been proven that other immune 
cells such as resting lymphocytes and NK cells express mem-
brane-bound APN as well. In contrast to myelomonocytic 
cells, these cells express low amounts of APN; however, their 
CD 13 surface expression is increased by different mitogenic 
stimuli or after co-cultivation with synoviocytes or other 
CD13-expressing cells [16,22-24]. The functional relevance 
of this induction is unclear as yet, but it has been proposed 
that APN like other membrane-bound peptidases such as neu-
tral endopeptidase (E.C. 3.4.24.11, CD10), aminopeptidase A 
(E.C. 3.4.11.7) or angiotensin-converting enzyme (E.C. 
3.4.15.1, CD 143) may function as a regulatory molecule that 
degrades bioactive peptides [5]. The induction of CD 13 on T-
cells is generally accompanied by an increase of the corre-
sponding enzymatic activity and APN mRNA level [16,24]. 
To gain insight into the mechanism underlying the CD 13 in-
duction on T-lymphocytes, we investigated the transcriptional 
regulation of the APN gene. Actinomycin D inhibits nearly all 
RNA synthesis by intercalation into DNA. Furthermore, it 
also prevents the binding of ribosomes to transcripts and, 
therefore, subsequent protein synthesis [25]. Using this ap-
proach, the half-lives of the APN transcript were determined 
in different immune cells. The average half-life span of human 
transcripts is about 10 h, ranging from less than 15 min to 
more than 24 h [26]. Talking into account these data, the 
APN half-lives of 3.5-6 h could be considered as medium. 
Since no data on APN half-life time in any tissue are avail-
able, the data obtained in this study can only be compared to 
those of other glycoproteins. Comparable half-life times were 
described for annexin VII (3-6 h), lactoferrin (8-9 h) and 
myeloperoxidase (4-5 h) [27,28]. 
The transcriptional regulation of APN gene expression was 
revealed by two excellent studies. Both Shapiro and co-work-
ers as well as Olsen and co-workers identified separate pro-
moters that initiate transcription in intestinal epithelial and 
myeloid cells. In epithelial cells, transcription is controlled 
by a classical promoter containing a TATA box immediately 
upstream to the first codon of APN, whereas an alternative 
GC-rich promoter located about 8 kb upstream from coding 
region is active in myeloid cells as well as in fibroblasts 
[29,30]. Both promoter regions considerably differ with respect 
to transcription factor-binding sites. The transcription factors 
LF-B1 and Sp-1 represent the major regulators in epithelial 
and liver cells, whereas myb and Ets-2 both transactivate 
CD13 expression in myeloid cells [29,31]. The importance of 
promoter-mediated regulation is emphasised by reports show-
ing that modulation of APN surface expression on endome-
trial cells and leukaemic B-cells is directly linked to the activ-
ity of the tissue-specific APN gene promoter [32,33]. 
The transcription of the APN gene in hematopoietic cells is 
controlled by the alternative promoter [31]. RNA synthesis 
inhibition leads to a linear decrease of steady-state APN 
mRNA levels with half-life times of 3.5-6 h in different hem-
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atopoietic cells. Therefore, it could be assumed that factors 
involved in A P N m R N A degradation seem to be more stable 
than transcription factors which control the constitutive APN 
gene expression in resting T-cells. The activation-dependent 
induction of APN gene expression in T-cells may be due to 
the action of new transcription factors, an assumption which 
is supported by the increase of APN-promoter activity de-
tected in stimulated T-cells. Shapiro and co-workers identified 
putative Sp-1, PU- AP-2, myb- and ETF-binding sites in the 
alternative promoter which probably contributes to the tran-
scriptional activation of the APN gene [30]. However, the 
prolonged half-life time of APN-transcript in stimulated T-
cells as well as the discrepancy between the 2.7-fold increase 
of A P N transcript level and the 1.7-fold rise of transcription 
rate in these cells suggest the appearance or disappearance of 
factors directly involved in the degradation of A P N transcript. 
Post-transcriptional regulation of m R N A decay after stimula-
tion is a common regulatory mechanism described for other 
transcripts such as the C D 11 a, the mMCP-2 (chymase-homo-
log protein) [34,35]. 
Taken together, the results of this study clearly show that 
the APN gene expression of stimulated T-cells is controlled at 
both the transcriptional and post-transcriptional level. Since 
stabilization of A P N m R N A was observed in other stimulated 
cells such as H9 and N K cells, as well, it may be concluded 
that this process represents a general mechanism of A P N in-
duction in hematopoietic cells. 
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